Arrowhead Pharma stock rating reiterated at Buy by TD Cowen

Arrowhead posted FY2026 results with EPS $0.22 vs $0.12 expected (+83.33% surprise) and revenue $264M vs $227.61M expected, while the stock trades at $60.51 (up 336% YTD) with a market cap of $8.46B. Clinical data for monotherapy ARO-INHBE (WVE-007) showed weight/fat-loss below investor expectations, prompting hypothesis-generating studies and expanded trials (including combinations with tirzepatide) and Phase II planning; preclinical ARO-ALK7 data suggest potentially greater weight loss. Analysts remain mixed: TD Cowen reiterated Buy, BofA trimmed its PT to $81 from $84 (Buy), Leerink kept Market Perform $61, and Goldman maintained Neutral $85, implying limited near-term consensus upside despite strong earnings.

Analysis

The readout noise around novel RNAi/metabolic programs has shifted the narrative from blockbuster monotherapy to niche, adjunctive use — that is the second-order revenue consequence the market underprices. If these mechanisms are ultimately positioned as maintenance or combo assets, peak sales per asset will compress but contract durations and pricing power versus one-time or short-duration therapies may improve; valuation models should reallocate probability mass from single-agent peak revenue to multi-year, lower-topline annuities.

Competitive dynamics favor incumbent incretin franchises and large combo partners who can bundle GLP/GIP/other agents with RNAi add-ons; smaller platform players without a clear combo roadmap face disproportionate trial and commercial risk. This also raises bargaining leverage for biotech partners and OEMs supplying peptide drug manufacturing and co-formulation services — a potential win for CDMOs and for partners with deep payer-engagement experience.

Near-term market behavior will be binary and volatility-driven around heterogeneous readouts; expect 20–40% swings in affected names on incremental data or analyst probability adjustments. The primary risks that would reverse this rotation are: a clear monotherapy signal that matches or beats market-expected incretin efficacy, or a payer/HTA playbook that allows premium reimbursement for adjunctive therapy — both would re-expand TAM and re-rate multiples quickly.

Key Decisions for Investors

• Long ARWR via a 9–12 month call spread sized 1–2% portfolio: buy deep-OTM to ATM calls and sell higher-strike calls to finance premium. Rationale: captures asymmetric upside if combo/adjunct positioning proves commercial; capped loss = premium (limited), target 3:1 reward if favorable readouts compress uncertainty.
• Hedge or short WVE equity on 3–6 month horizon (or buy put protection): size as a small opportunistic short (0.5–1% portfolio) to reflect platform execution risk and market repricing of monotherapy hopes. Risk: binary positive surprise; cap exposure and use puts to limit upside loss.
• Relative-value pair — long SRPT, short ARWR (equal dollar exposure) over 6–12 months: rationale is to capture partner optionality and lower idiosyncratic pipeline execution risk at SRPT while being short the higher-volatility repositioning name. Expect positive carry if market rewards partner stability; unwind if SRPT shows material program setbacks.
• Volatility play around next major readout: buy a short-dated straddle or long-dated calendar debit spread into event windows (small size, 0.5–1% portfolio). Objective is to monetize a large directional move without committing to binary outcome; exit on 50% of realized move or 10 days post-event to avoid theta bleed.